Abstract
Background People of minority ethnic background may be disproportionately affected by severe COVID-19 for reasons that are unclear. We sought to examine the relationship between ethnic background and (1) hospital admission for severe COVID-19; (2) in-hospital mortality.
Methods We conducted a case-control study of 872 inner city adult residents admitted to hospital with confirmed COVID-19 (cases) and 3,488 matched controls randomly sampled from a primary healthcare database comprising 344,083 people resident in the same region. To examine in-hospital mortality, we conducted a cohort study of 1827 adults consecutively admitted with COVID-19. Data collected included hospital admission for COVID-19, demographics, comorbidities, in-hospital mortality. The primary exposure variable was self-defined ethnicity.
Results The 872 cases comprised 48.1% Black, 33.7% White, 12.6% Mixed/Other and 5.6% Asian patients. In conditional logistic regression analyses, Black and Mixed/Other ethnicity were associated with higher admission risk than white (OR 3.12 [95% CI 2.63-3.71] and 2.97 [2.30-3.85] respectively). Adjustment for comorbidities and deprivation modestly attenuated the association (OR 2.28 [1.87-2.79] for Black, 2.66 [2.01-3.52] for Mixed/Other). Asian ethnicity was not associated with higher admission risk (OR 1.20 [0.86-1.66]). In the cohort study of 1827 patients, 455 (28.9%) died over a median (IQR) of 8 (4-16) days. Age and male sex, but not Black (adjusted HR 0.84 [0.63-1.11]) or Mixed/Other ethnicity (adjusted HR 0.69 [0.43-1.10]), were associated with in-hospital mortality. Asian ethnicity was associated with higher in-hospital mortality (adjusted HR 1.54 [0.98-2.41]).
Conclusions Black and Mixed ethnicity are independently associated with greater admission risk with COVID-19 and may be risk factors for development of severe disease. Comorbidities and socioeconomic factors only partly account for this and additional ethnicity-related factors may play a large role. The impact of COVID-19 may be different in Asians.
Funding sources British Heart Foundation (CH/1999001/11735 and RE/18/2/34213 to AMS); the National Institute for Health Research Biomedical Research Centre (NIHR BRC) at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London (IS-BRC-1215-20006); and the NIHR BRC at South London and Maudsley NHS Foundation Trust and King’s College London (IS-BRC-1215-20018).
Competing Interest Statement
JTHT received research funding from Bristol-Myers-Squibb and iRhythm Technologies and holds shares less than 5,000 UK pounds in Glaxo Smithkline and Biogen. All other authors declare that they have no competing interests.
Funding Statement
RZ is supported by a Kings Prize Fellowship. RB is supported by the Kings College London UK Medical Research Council (MRC) Skills Development Fellowship programme (MR/R016372/1) and the National Institute for Health Research Biomedical Research Centre (NIHR BRC) at South London and Maudsley NHS Foundation Trust and Kings College London (SLAM-KCL; IS-BRC-1215-20018). DMB holds a UK Research and Innovation (UKRI) Fellowship as part of Health Data Research UK (HDRUK) MR/S00310X/1. KOG is supported by an MRC Clinical Training Fellowship. This study was supported in part by the British Heart Foundation (CH/1999001/11735 and RE/18/2/34213 to AMS); the NIHR BRC at Guys & St Thomas NHS Foundation Trust and Kings College London (IS-BRC-1215-20006); and the SLAM-KCL NIHR BRC. RJBD is also supported by HDRUK; and the UKRI London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare; the BigData@Heart Consortium (Innovative Medicines Initiative-2 Joint Undertaking Grant No. 116074 of the European Union Horizon 2020 programme); the NIHR University College London Hospitals Biomedical Research Centre and Research Informatics Unit; and the NIHR Applied Research Collaboration South London at Kings College Hospital NHS Foundation Trust. AMS is also supported by the Fondation Leducq. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study adhered to the principles of the UK Data Protection Act 2018 and UK National Health Service (NHS) information governance requirements. De-identified data from patients admitted to KCHFT were analysed under London SE Research Ethics Committee approval (reference 18/LO/2048) granted to the Kings Electronic Records Research Interface (KERRI). Access to Lambeth DataNet was under a project-specific approval granted by Lambeth Public Health Caldicott Guardian, 30 April 2020; additional informed consent was not required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files.
